Theriva Biologics Shares Are Trading Higher After the Company Announced It Will Present Preclinical Data for the Potential Synergy of VCN-01 and First-line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
Theriva Biologics宣佈將在美國細胞與基因療法學會第27屆年會上公佈有關 VCN-01 和一線胰腺癌化療方案的潛在協同作用的臨床前數據，此後，該公司股價走高